Development of alternative therapies for the treatment of combined oxidative phosphorylation deficiency Type 1 (COXPD1) caused by mutations in GFM1.
MGD, directed by Rubén Rabadán and Rubén Zapata. It is part of Juan Carlos Izpisua Belmonte’s lab at UCAM Hitech, Sport & Health Innovation Hub.
To determine the efficacy of a combinatorial therapy with NAD+ precursors and redox modulators.
The MGD group studies regulation in diseases in a broad context, ranging from inherited diseases to those related to aging. It is also very interested in the metabolic processes that underlie these diseases and others derived from failures in the metabolism itself, as well as their gene regulation and the application of gene editing techniques (e.g. CRISPR/Cas9) for their treatment.